1
|
Ferguson WS and Goorin AM: Current
treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001.
|
2
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009.
|
3
|
Nieto MA: The snail superfamily of
zinc-finger transcription factors. Nat Rev Mol Cell Biol.
3:155–166. 2002.
|
4
|
Ferrari S, Smeland S, Mercuri M, et al;
Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy
with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and
doxorubicin for patients with localized osteosarcoma of the
extremity: a joint study by the Italian and Scandinavian Sarcoma
Groups. J Clin Oncol. 23:8845–8852. 2005.
|
5
|
Yang H, Zhang Y, Zhou Z, et al: Snail-1
regulates VDR signaling and inhibits 1,25(OH)-D3 action
in osteosarcoma. Eur J Pharmacol. 670:341–346. 2011.
|
6
|
Perez-Moreno M, Jamora C and Fuchs E:
Sticky business: orchestrating cellular signals at adherens
junctions. Cell. 112:535–548. 2003.
|
7
|
Takeichi M: Morphogenetic roles of classic
cadherins. Curr Opin Cell Biol. 7:619–627. 1995.
|
8
|
Huber O, Bierkamp C and Kemler R:
Cadherins and catenins in development. Curr Opin Cell Biol.
8:685–691. 1996.
|
9
|
De Wever O and Mareel M: Role of tissue
stroma in cancer cell invasion. J Pathol. 200:429–447. 2003.
|
10
|
Vleminckx K, Vakaet L Jr, Mareel M, et al:
Genetic manipulation of E-cadherin expression by epithelial tumor
cells reveals an invasion suppressor role. Cell. 66:107–119.
1991.
|
11
|
Perl AK, Wilgenbus P, Dahl U, Semb H and
Christofori G: A causal role for E-cadherin in the transition from
adenoma to carcinoma. Nature. 392:190–193. 1998.
|
12
|
Batlle E, Sancho E, Franci C, et al: The
transcription factor snail is a repressor of E-cadherin gene
expression in epithelial tumour cells. Nat Cell Biol. 2:84–89.
2000.
|
13
|
Kansara M and Thomas DM: Molecular
pathogenesis of osteosarcoma. DNA Cell Biol. 26:1–18. 2007.
|
14
|
Tang N, Song WX, Luo J, et al:
Osteosarcoma development and stem cell differentiation. Clin Orthop
Relat Res. 466:2114–2130. 2008.
|
15
|
Meyers PA, Schwartz CL, Krailo MD, et al;
Children’s Oncology Group. Osteosarcoma: the addition of muramyl
tripeptide to chemotherapy improves overall survival - a report
from the Children’s Oncology Group. J Clin Oncol. 26:633–638.
2008.
|
16
|
Kager L, Zoubek A, Potschger U, et al;
Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary
metastatic osteosarcoma: presentation and outcome of patients
treated on neoadjuvant Cooperative Osteosarcoma Study Group
protocols. J Clin Oncol. 21:2011–2018. 2003.
|
17
|
Klymkowsky MW and Savagner P:
Epithelial-mesenchymal transition: a cancer researcher’s conceptual
friend and foe. Am J Pathol. 174:1588–1593. 2009.
|
18
|
Peinado H, Del Carmen Iglesias-de la Cruz
M, Olmeda D, et al: A molecular role for lysyl oxidase-like 2
enzyme in snail regulation and tumor progression. EMBO J.
24:3446–3458. 2005.
|
19
|
Yang J, Mani SA, Donaher JL, et al: Twist,
a master regulator of morphogenesis, plays an essential role in
tumor metastasis. Cell. 117:927–939. 2004.
|
20
|
Tlsty TD and Coussens LM: Tumor stroma and
regulation of cancer development. Annu Rev Pathol. 1:119–150.
2006.
|
21
|
Yehiely F, Moyano JV, Evans JR, et al:
Deconstructing the molecular portrait of basal-like breast cancer.
Trends Mol Med. 12:537–544. 2006.
|
22
|
Lacroix M, Toillon R and Leclercq G:
Stable ‘portrait’ of breast tumors during progression: data from
biology, pathology and genetics. Endocr Relat Cancer. 11:497–522.
2004.
|
23
|
Zhuang Z, Lininger RA, Man YG, et al:
Identical clonality of both components of mammary carcinosarcoma
with differential loss of heterozygosity. Mod Pathol. 10:354–362.
1997.
|
24
|
Berx G, Cleton-Jansen AM, Strumane K, et
al: E-cadherin is inactivated in a majority of invasive human
lobular breast cancers by truncation mutations throughout its
extracellular domain. Oncogene. 13:1919–1925. 1996.
|
25
|
Castro Alves C, Rosivatz E, Schott C, et
al: Slug is overexpressed in gastric carcinomas and may act
synergistically with SIP1 and Snail in the down-regulation of
E-cadherin. J Pathol. 211:507–515. 2007.
|
26
|
Saegusa M, Hashimura M, Kuwata T and
Okayasu I: Requirement of the Akt/beta-catenin pathway for uterine
carcinosarcoma genesis, modulating E-cadherin expression through
the transactivation of slug. Am J Pathol. 174:2107–2115. 2009.
|
27
|
Moll R, Mitze M, Frixen UH and Birchmeier
W: Differential loss of E-cadherin expression in infiltrating
ductal and lobular breast carcinomas. Am J Pathol. 143:1731–1742.
1993.
|
28
|
Côme C, Magnino F, Bibeau F, et al: Snail
and slug play distinct roles during breast carcinoma progression.
Clin Cancer Res. 12:5395–5402. 2006.
|
29
|
Peinado H, Ballestar E, Esteller M and
Cano A: Snail mediates E-cadherin repression by the recruitment of
the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell
Biol. 24:306–319. 2004.
|
30
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: an alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007.
|
31
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006.
|
32
|
Barrallo-Gimeno A and Nieto MA: The Snail
genes as inducers of cell movement and survival: implications in
development and cancer. Development. 132:3151–3161. 2005.
|
33
|
Martin TA, Goyal A, Watkins G and Jiang
WG: Expression of the transcription factors snail, slug, and twist
and their clinical significance in human breast cancer. Ann Surg
Oncol. 12:488–496. 2005.
|
34
|
Parker BS, Argani P, Cook BP, et al:
Alterations in vascular gene expression in invasive breast
carcinoma. Cancer Res. 64:7857–7866. 2004.
|